China approves Innovent’s picankibart: first domestic IL‑23p19

China’s National Medical Products Administration authorized Innovent Biologics’ picankibart (IBI‑112), branded Pecondle, for moderate to severe plaque psoriasis—marking the country’s first domestically developed IL‑23p19 antibody approval. The recombinant monoclonal targets the IL‑23p19 subunit and adds a locally produced alternative to international IL‑23 therapies. Innovent’s approval follows an NDA accepted in 2024 and strengthens domestic biologics capabilities in immunodermatology while broadening patient access in China.